Chronopharmacokinetic Study of a New Immunosuppressive Agent, FK 506, in Mice

FK 506: a new therapeutic agent for severe recalcitrant psoriasis.

BETWEEN 12 and 18 months ago we treated three patients with FK S06 who had severe psoriasis that was refractory to conventionai therapy and four patients with w,despread incidental psonasis before undergoing hean or liver transplantation under FK 506. All had dramatic resolution of psonasis. which remaIned in remission as long as full-dose therapy was provided. Serial skin biopsies had a rapid ...

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

The immuno-pharmacological profile of a novel immunosuppressive agent, FK-506 produced by a streptomycete, is presented here. We proceeded to test the effect of the agent on various in vitro immune systems. It showed that mixed lymphocyte reaction, cytotoxic T cell generation, the production of T cell-derived soluble mediators such as interleukin 2 (IL-2), interleukin 3 and gamma-interferon and...

A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent.

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

R ECENT STUDIES have described a new potent immunosuppressive drug FK-506 (FK) that induces considerable prolongation of allograft survival.'·) This drug is isolated from Streptomyces tsukubaensis. has a molecular weight of 822 daltons, and is structurally different from cyclosporine A (CsA). In vitro investigations have demonstrated a strong inhibitory effect on lymphocyte activation that appe...

Notes on FK 506.